Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-32729463 vs Linezolid in cSSSI
NCT01128530Phase 2Completed
- Sponsor
- Furiex Pharmaceuticals
- Start
- Jun 2010
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of delafloxacin in Skin and Skin Structure Infection (SSSI) (2 arms), sponsored by Furiex Pharmaceuticals. Primary endpoints: Cessation of spread or reduction in the size of the primary infection site lesion and Defervescence. Started Jun 2010; status: completed.
02
Drugs
delafloxacin
03
Conditions
Skin and Skin Structure Infection (SSSI)
Beyond the preview
Go deeper on NCT01128530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01128530.